Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide for lithium-induced nephrogenic diabetes insipidus
NL-OMON35668Phase 2Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of acetazolamide in Arginine Vasopressin Resistance (AVP-R), sponsored by Radboud University Medical Center. Primary endpoints: Maximal urine volume reduction after dDAVP stimulation and Maximal urine osmolality after dDAVP stimulation. Started Jan 2015; status: active, not recruiting.
02
Drugs
acetazolamide
03
Conditions
Arginine Vasopressin Resistance (AVP-R)
Beyond the preview
Go deeper on NL-OMON35668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35668.